Recent News

• 08.06.2026 - Ocugen Provides Business Update with Second Quarter 2026 Financial Results
• 07.31.2026 - Ocugen to Participate in Upcoming August Investor Conferences
• 07.29.2026 - Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
• 07.28.2026 - Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
• 07.13.2026 - Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
• 07.01.2026 - Ocugen to Participate in Upcoming July Industry Conferences
• 06.02.2026 - Ocugen to Participate in Upcoming June Investor and Industry Conferences
• 05.14.2026 - Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
• 05.13.2026 - Ocugen to Participate in Upcoming May Scientific and Investor Conferences
• 05.05.2026 - Ocugen Provides Business Update with First Quarter 2026 Financial Results

Recent Filings

• 08.07.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - EX-99.1 EX-99.1
• 08.06.2026 - 8-K Current report
• 07.30.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 07.30.2026 - DEF 14A Other definitive proxy statements
• 07.29.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.20.2026 - PRE 14A Other preliminary proxy statements
• 07.13.2026 - 8-K Current report
• 07.13.2026 - EX-99.1 EX-99.1